Biohaven Ltd.

NYSE:BHVN

Biotechnology

Healthcare
$12.90 -1.62%

-$0.22 today

Market cap
$1.95B
Beta
3.31
P/E (TTM)
-3.1
EPS (TTM)
-$4.39
52W Low $7.48High $18.57

Volume 2.32M

Average 2.47M

BHVN Depreciation & Amortization

Non-cash asset write-downs added back to net income because no cash left the business.

Biohaven Ltd.NYSE: BHVN

Depreciation & Amortization · Q2 FY2026 · quarter ended Jun 2026

Depreciation & amortization grows, but more slowly than its trailing trend

Q2 FY2026 depreciation & amortization of $2.26M rose 14.2% year over year, behind the +18.9% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 4.5% from the prior quarter. Over 3 fiscal years it compounded at +92.7% a year.

Context

  • Depreciation & amortization increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +14.2% toward the trailing-twelve-month pace of +18.9%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$2.26M-4.5% QoQ
Last fiscal yearDec 2025
$9.92M+26.3% YoY
LTMJun 2026
$10.32M+18.9% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+14.2%——
1 year+26.3%——
3-year CAGR+92.7%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the cash flow

Latest · FY2025
9.92M USD
Year-over-year change
+26.3%
4-year CAGR
+63.4%

Depreciation & Amortization vs competitors

How BHVN compares with its peers on the latest reported figures

  • Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +18.9% is the 5th highest of 11, against a peer median of +6.7%.
  • Over three fiscal years its annual growth of +92.7% compares with a peer median of +5.3%.
BHVN Competitors
Depreciation & Amortization for BHVN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ABCLAbCellera Biologics Inc.LTM Sep 2026$32.16M USD-7.6%-4.5%47.4%
XERSXeris Biopharma Holdings, Inc.LTM Mar 2026$12.47M USD+3.0%-1.4%4.0%
BHVNBiohaven Ltd.LTM Jun 2026$10.32M USD+18.9%+92.7%—
NTLAIntellia Therapeutics, Inc.LTM Mar 2026$9.99M USD-2.7%+10.7%15.1%
IMNMImmunome, Inc.LTM Sep 2026$3.76M USD+35.4%+67.3%—
CLDXCelldex Therapeutics, Inc.LTM Sep 2026$3.73M USD+10.4%+5.3%3333.9%
IMCRImmunocore Holdings plcLTM Mar 2026$3.36M USD-17.0%-23.1%0.9%
ZBIOZenas BioPharma, Inc.LTM Mar 2026$1.05M USD-922.8%——
SIONSionna Therapeutics, Inc.LTM Mar 2026$904K USD+36.8%——
VERAVera Therapeutics, Inc.LTM Jun 2026$652K USD+130.4%——
PHVSPharvaris N.V.LTM Sep 2026€483K EUR+19.4%+39.9%—
Peer median (excluding BHVN) —+6.7%+5.3%15.1%

Competitors are the stored peer set for BHVN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(213.8M)(570.28M)(408.17M)(846.42M)(738.82M)
Depreciation & Amortization1.39M1.39M6.91M7.86M9.92M
Deferred Income Tax00000
Stock-Based Compensation65.64M193.56M28.79M71.96M112.36M
Change in Working Capital1.66M(28.6M)24.61M16.81M1.36M
Accounts Receivables00000
Inventory00000
Accounts Payables1.03M5.93M4.87M710K(6.39M)
Other Working Capital639K(34.53M)19.74M16.1M7.74M
Other Non-Cash Items(740K)106.25M16.13M167.34M5.74M
Operating Cash Flow(145.84M)(297.69M)(331.73M)(582.45M)(609.44M)
Capital Expenditures(938K)(41.07M)(3.05M)(4.05M)(715K)
Acquisitions (Net)1.88M00391K0
Purchases of Investments0(263.72M)(194.12M)(745.68M)(266.88M)
Sales of Investments00327M504.36M570M
Other Investing Activities0000(1.85M)
Investing Cash Flow944K(304.79M)129.83M(244.97M)300.56M
Debt Repayment0449.13M00250M
Common Stock Issued0283.8M243.23M675.52M189.31M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities138.45M34.66M(31.32M)2.26M(194K)
Financing Cash Flow138.45M767.6M211.91M677.77M439.12M
Effect of Forex Changes0429K(497K)75K(3K)
Net Change in Cash(6.45M)165.55M9.52M(149.58M)130.24M
Free Cash Flow(146.78M)(338.76M)(334.77M)(586.5M)(610.15M)

Biohaven Ltd.

NYSE:BHVN

Intrinsic Alpha fair value

Locked

Current Price

$12.90

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.